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In patients with chronic hepatitis C, advanced fibrosis and cirrhosis are associated with lower
rates of sustained virologic response (SVR) to interferon (IFN)-based therapy. In this study,
we assessed virologic response to retreatment with peginterferon alfa-2a and ribavirin
(RBV), as a function of the baseline fibrosis score (Ishak staging) and platelet count, in 1,046
patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis
(HALT-C) Trial. All patients had failed prior treatment with IFN or peginterferon  RBV
and had Ishak fibrosis scores > 3. Four groups of patients with increasingly severe liver
disease were compared: (A) bridging fibrosis (Ishak 3 and 4) with platelet counts >125,000/
mm3 (n  559); (B) bridging fibrosis with platelet counts <125,000/mm3 (n  96); (C)
cirrhosis (Ishak 5 and 6) with platelet counts >125,000/mm3 (n  198); and (D) cirrhosis
with platelet counts <125,000/mm3 (n  193). SVR rates were 23%, 17%, 10%, and 9% in
groups A, B, C, and D, respectively (P < .0001 for trend). Reduction in SVR as a function of
increasingly severe disease was independent of age, percent African American, HCV geno-
type, HCV level, and type of prior therapy. Dose reduction lowered SVR frequencies, but to
a lesser extent than disease severity. By logistic regression, cirrhosis (P < .0001) was the
major determinant that impaired virologic response, independent of dose reduction or
platelet count. In conclusion, disease severity is a major independent determinant of rate of
SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize
antiviral therapy in these “difficult-to-cure” patients. (HEPATOLOGY 2006;44:1675-1684.)
Abbreviations: HCV, hepatitis C virus; RBV, ribavirin; SVR, sustained virologic response; PEG-IFN, pegylated interferon; INR, international normalized ratio.
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Currently, more than 2.7 million persons living inthe United States are actively infected with thehepatitis C virus (HCV), and an estimated 8,000
to 10,000 deaths each year are attributable to complica-
tions of chronic hepatitis C.1-3 Modeling, based on the
age-stratified prevalence of HCV infection and the
known natural history of chronic hepatitis C, suggests
that the number of persons infected for 20 or more years
will continue to rise and peak in 2015.4 As a consequence,
cases who decompensate, advance to hepatocellular carci-
noma, and need liver transplantation will increase dra-
matically over the ensuing decade.5-10
Antiviral therapy of chronic hepatitis C has improved
substantially11; however, virologic responses are lower in
patients with advanced hepatic fibrosis or cirrhosis. Re-
sults of trials involving pegylated interferons-alfa 2a or 2b
in combination with ribavirin (RBV) showed that sus-
tained virologic response (SVR) rates ranged from 41% to
44% in patients with bridging fibrosis or cirrhosis, com-
pared with an SVR of up to 65% in those with less ad-
vanced hepatic fibrosis.12-14 All of these studies involved
patients not previously treated and included persons with
compensated cirrhosis who were clinically and biochem-
ically stable. Reasons for diminished virologic responses
in patients with cirrhosis are incompletely defined.
The ongoing Hepatitis C Antiviral Long-term Treat-
ment against Cirrhosis (HALT-C) Trial is examining the
impact of treatment in persons with chronic hepatitis C
and advanced hepatic fibrosis.15 Persons eligible for this
trial had to have histologically documented bridging fi-
brosis or cirrhosis and to have failed to respond to prior
antiviral treatment. Eligible patients were treated during a
lead-in phase with pegylated interferon (PEG-IFN)
alfa-2a plus RBV. In this report, we analyze the relation-
ship between the severity of liver disease at baseline and
the virologic response to treatment during the lead-in
phase of the trial.
Patients and Methods
The HALT-C Trial is being conducted at 10 clinical
centers in the United States; details of the study design
and entry criteria have been reported previously.15 The
study protocol was approved by the institutional review
board at each participating center, and written consent
was obtained from all patients.
Patient Population. Study patients had detectable
HCV RNA in serum and histological evidence of either
bridging fibrosis (Ishak score 3 or 4) or cirrhosis (Ishak
score 5 or 6) within 12 months of enrollment. Patients
were also required to have evidence of nonresponse to
their most recent course of treatment with a minimum of
12 weeks of standard interferon, 3 MU thrice weekly,
with or without RBV. A small number of nonresponders
to PEG-IFN monotherapy (n  38) or PEG-IFN/RBV
(n  61) were enrolled. Exclusions to enrollment were
other co-existent liver disorders, a liver biopsy displaying
3 or 4 stainable iron (Prussian blue stain),16 a Child-
Turcotte-Pugh score  7; human immunodeficiency vi-
rus positivity; or a history of variceal hemorrhage, ascites,
or hepatic encephalopathy. Baseline laboratory values
that excluded patients from enrollment included a serum
creatinine 1.5 mg/dL, absolute neutrophil count
1,000/mm3, platelet count 50,000/mm3, or hemo-
globin level 11.0 g/dL. A total of 1,145 patients entered
the HALT-C trial, but only patients with HCV RNA
results at week 20 on treatment and at week 72 during
follow-up (n  1,046) were included in this analysis.
Defining Severity of Liver Disease. Severity of liver
disease was categorized, a priori, according to the Ishak
fibrosis score on baseline liver biopsy and platelet count.
The platelet count was included in our model of disease
severity to detect two sets of patients not readily definable
by other means: those with presumed cirrhosis but whose
liver biopsy demonstrated only fibrosis due to sampling
error, and those who truly lacked histological cirrhosis but
who had advanced fibrosis and portal hypertension.
Both Ishak fibrosis score and platelet count correlated
strongly with serum bilirubin and albumin, prothrombin
time/international normalized ratio (INR), endoscopic
findings of portal hypertensive gastropathy or varices, and
ultrasonographic evidence of splenomegaly (P  .0001
for all). The cutoff we chose for platelet count was defined
by the median platelet count of trial patients with cirrho-
sis, which was 125,000/mm3. Two histological groups,
showing either fibrosis (Ishak score 3 or 4) or cirrhosis
(Ishak score 5 or 6), were further subdivided into those
with platelet counts of  or 125,000/mm3, yielding
group A, patients with fibrosis and platelet counts
125,000/mm3; group B, patients with fibrosis and
platelet counts 125,000/mm3; group C, patients with
cirrhosis and platelet counts 125,000/mm3; and group
D, patients with cirrhosis and platelet counts 125,000/
mm3.
Study Design. Patients were treated with PEG-IFN
(Pegasys, Roche Laboratories, Nutley, NJ) and RBV
(Copegus, Roche Laboratories, Nutley, NJ). Twelve of
the 1,046 patients were intolerant of RBV during previ-
ous therapy and did not receive RBV, and 15 additional
patients were started on lower doses of RBV. During
treatment, patients were monitored monthly for side ef-
fects and changes in serum tests of liver chemistry, com-
plete blood counts, and serum HCV RNA levels.
Definitions of Response. Hepatitis C virus RNA was
considered undetectable based on a value of 100 IU/mL
1676 EVERSON ET AL. HEPATOLOGY, December 2006
by the Roche COBAS Amplicor HCV Test, v. 2.0. To
provide sufficient time for completion of virologic testing
and randomization into the maintenance phase of the
HALT-C Trial by week 24, we defined on-treatment re-
sponse as negative serum HCV RNA at week 20
(VR20).15 SVR was defined as the absence of detectable
serum HCV RNA at week 72, 24 weeks after discontin-
uation of treatment.
Dose Reduction
According to protocol, the dose of PEG-IFN was re-
duced stepwise from 180 to 135 to 90 and then to 45
g/week if the neutrophil count declined to 750/mm3
or the platelet count to 50,000/mm3. Ribavirin was
reduced from 1,000 or 1,200 to 600 mg/d if the hemo-
globin declined to 10 g/dL or by more than 4 g/dL from
the pretreatment baseline. Investigators managing the pa-
tient could reduce doses or discontinue one or both drugs
for other clinical reasons. Prior doses of PEG-IFN and
RBV could be reinstituted if adverse events or cytopenias
resolved.
The doses of both PEG-IFN and RBV actually taken
by each patient were evaluated by reviewing nursing
records and patient diaries.15 The amounts taken by each
patient during the first 20 weeks were expressed as a per-
centage of the target doses. The target doses were 180
g/wk PEG-IFN and 1,000 or 1,200 mg/d RBV. Dose
discontinuation was defined as permanently stopping
RBV by week 16. In patients who did not discontinue
therapy, the actual amounts received were categorized as
full doses if they exceeded 80% of the target doses of both
PEG-IFN and RBV and as reduced doses if they were less
than 80% of the target doses.
Liver Histology. Biopsy specimens were reviewed by
a team of pathologists representing each of the clinical
centers participating in this trial. Length and fragmenta-
tion were determined, and all biopsies were assigned an
inflammatory and fibrosis score based on the criteria of
Ishak.17 The degree of steatosis and intensity of iron stain-
ing were quantified.16,18
Assessment of HCV RNA
All serum samples were frozen at 70°C and shipped
to the virology core laboratory at the University of Wash-
ington for analysis.15 Samples negative by quantitative
COBAS Amplicor HCV Monitor test v.2.0 (Roche Mo-
lecular Systems, Branchburg, NJ) were retested with the
qualitative COBAS Amplicor HCV Test, v. 2.0 assay
(Roche Molecular Systems, Branchburg, NJ), which has a
sensitivity of 100 IU/mL.
Statistical Analyses
Chi-square and ANOVA were used to identify vari-
ables that were significantly different among the four pa-
tient groups, A through D. Predictors of virologic
response were assessed with chi-square tests and t tests.
Predictors that were related to response in univariate anal-
yses were entered into multivariate logistic regression to
assess their relative importance. The linear relationship
between response and the four groups was assessed by a
logistic regression with the four groups coded 1 to 4.
Analyses were performed with the Statistical Analysis Sys-
tem version 9.1.
Results
Characterization of Study Groups
Patient characteristics of the four study groups are
shown in Table 1. Mean age, ethnicity, type of prior ther-
apy, percentage of patients with a history of drinking al-
cohol or of smoking, and use of nearly all medications
were similar among the four groups. Body mass index was
slightly higher in the groups with cirrhosis (P  .04 for
linear trend).
The lifetime number of alcoholic drinks increased
from groups A to D (P  .03), but the proportion of
patients using alcohol at baseline was greatest in group A,
the group with the least severe disease P  .004). Thus, no
consistent relationship was apparent between alcohol ex-
posure and severity of liver disease. Highly significant lin-
ear increases were found in the Beck Depression Index
(6.7-8.3) and use of nonselective -blockers (2%-8%) for
treatment of portal hypertension from groups A to D
(P  .0081 and P  .0004, respectively).
Baseline laboratory, histologic, ultrasonographic, and
endoscopic results are given in Table 2. Fewer patients in
group B were infected with HCV genotype 1 (P  .02).
HCV RNA levels linearly declined from groups A to D
(P  .0001). Patients in groups B and D had lower mean
white blood counts (WBC, P  .0001), absolute neutro-
phil counts (P  .0001), hemoglobin levels (P  .0016),
and platelet counts. Linear regression analysis demon-
strated that the serum bilirubin, INR, and aspartate ami-
notransferase:alanine aminotransferase ratio increased
while serum albumin decreased from group A to group D
(P  .0001 for all); however, results of these standard tests
were very similar between groups B and C. The propor-
tion of patients with a history of diabetes or glucose  126
mg/dL (P  .02) and the mean homeostasis model assess-
ment score (P  .01) were both lower in group A than in
other groups.
Ishak inflammation score (P  .0001) and Ishak fibro-
sis score increased from groups A to D, whereas the grade
of hepatic iron was similar among the four groups. Pa-
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tients in groups B and C had more hepatic steatosis (P 
.04). Splenomegaly and esophageal varices were more
common in patients with platelet counts 125,000/mm3
(Table 2, P  .0001 for both). Frequencies of esophageal
varices and portal hypertensive gastropathy increased
from groups A to D (P  .0001 for both trends, Table 2).
Fifteen percent of patients with fibrosis without histo-
logical evidence of cirrhosis had platelet counts
125,000/mm3 (group B). Despite the apparent lack of
histological cirrhosis in either groups A or B, patients in
group B had higher frequencies of splenomegaly, varices,
and portal hypertensive gastropathy—features suggestive
of portal hypertension—compared with patients in
group A (Table 2). Patients in group B had similar bio-
chemical impairment, similar frequencies of varices and
portal hypertensive gastropathy, and a higher frequency
of splenomegaly compared with the patients in group C,
whose liver biopsies showed cirrhosis (Table 2). Patients
in group D had more biochemical impairment and higher
frequencies of varices, portal hypertensive gastropathy,
and splenomegaly compared with patients in groups A, B,
and C (Table 2). Thus, the combination of platelet count
with the Ishak fibrosis score establishes a spectrum of
increasingly severe liver disease.
Virologic Response
Virologic responses at week 20 (VR20) declined from a
high of 41% in group A to a low of 18% for group D (Fig.
1A). The decline in VR20 from groups A to D was 36% to
16% for patients infected with HCV genotype 1 and 80%
to 35% for patients infected with non-1 genotypes. SVR
declined from 23% in group A to 9% in group D (Fig.
1B). The decline in SVR from groups A to D was 18% to
8% for patients infected with HCV genotype 1, and 64%
to 25% for patients infected with non-1 genotypes. Lo-
gistic regression analysis showed that the trendlines for
diminished virologic responses with increasing disease se-
verity from group A to group D were highly significant for
both VR20 and SVR (P  .0001).
Factors associated with diminished responsiveness to
PEG-IFN/RBV therapy have included HCV genotype-1,
high HCV RNA levels, African American heritage, and









Plt.< 125K P1 P2
Number of patients 559 96 198 193
Demographics
Age, years 49.5 50.5 50.5 50.2 .28 .33
Female 28% 25% 34% 21% .03 .31
Black 18% 8% 15% 13% .08 .11
Body Mass Index 29.4 29.4 30.2 30.2 .19 .04
Prior treatment
Previous combination therapy 72% 72% 75% 69% .56 .99
ETOH
Ever drank 83% 83% 84% 87% .74 .33
Total number of drinks in lifetime 16,324 18,986 19,379 22,593 .10 .01
Drinking at baseline 22% 11% 9% 19% .0006 .03
Smoking history
Ever smoked 77% 67% 79% 75% .13 .79
Smoke cigarettes now 31% 21% 30% 33% .20 .73
Pack-years of cigarettes 15.1 11.7 14.3 13.0 .18 .14
Depression
Beck BDI Depression score 6.7 7.2 7.9 8.3 .04 .004
Medications at Baseline
NSAID 8% 4% 9% 6% .33 .34
Cox2 Inhibitors 4% 2% 4% 4% .86 .99
Any anti-hypertensive 29% 38% 34% 38% .09 .02
Selective -blocker 7% 10% 10% 13% .03 .004
Nonselective -blocker 2% 4% 4% 8% .003 .0004
ACE inhibitors 9% 14% 16% 13% .06 .03
Thiazide diuretics 13% 16% 15% 17% .67 .23
Hypoglycemics 11% 15% 15% 15% .36 .11
Antidepressants/anxiolytics 30% 29% 31% 33% .92 .50
Anxiolytic 11% 14% 12% 12% .95 .81
SSRI antidepressant 18% 15% 16% 18% .87 .81
Non-SSRI antidepressant 9% 6% 10% 9% .75 .74
NOTE. The values listed in this table are means or percentages.
1P-values for differences in variables among the four groups were determined by t tests for means and chi-square tests for percentages.
2P values for trends in variables from groups A through D were determined by regression analysis.
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obesity, hepatic steatosis, and excess stainable hepatic
iron. In a multiple logistic regression analysis, we found
that none of these variables accounted for the decline in
either VR20 or SVR from groups A to D.
Rates of VR20 were 47%, 53%, 28%, and 21%, and
rates of SVR were 27%, 34%, 13%, and 11% in patients
whose prior therapy was interferon, PEG-IFN, interfer-
on/RBV, and PEG-IFN/RBV, respectively. However, by
multiple logistic regression analysis, type of prior treat-
ment did not account for the decline in either VR20 or
SVR from groups A to D.
Rates of VR20 and SVR were examined in relation to
four quartiles of platelet counts: 426,000 to 211,000/
mm3 (n  261 patients), 210,000 to 165,000/mm3 (n 
256 patients), 164,000 to 121,000/mm3 (n  265 pa-
tients), and 120,000 to 39,000/mm3 (n  263 patients).
Respective rates for VR20 were 42%, 35%, 35%, and
20%, and respective rates of SVR were 21%, 20%, 17%,
and 11%. Baseline platelet counts 120,000/mm3 were
associated with the lowest rates of VR20 and SVR.
Rates of VR20 and SVR were also evaluated according
to the following Ishak fibrosis scores: 3 (n  461 pa-
tients), 4 (n  193 patients), 5 (n  206), and 6 (n 
185). Respective rates for VR20 were 41%, 36%, 25%,
and 22%, and respective rates for SVR were 24%, 17%,
10%, and 10%. Rates for VR20 and SVR were approxi-
mately 50% lower in the patients with Ishak fibrosis
scores of 5 or 6.
Dose Reduction and Discontinuation
In a prior detailed analysis of our patients,19 only 3 of
80 patients who had discontinued RBV within the first 20
weeks achieved SVR. The SVR in those who continued
treatment with both PEG-IFN and RBV was compro-
mised by dose reductions, primarily of PEG-IFN. For
these reasons, in this study we examined the frequency of
discontinuation of RBV and analyzed the impact of dose
reductions on VR20 and SVR.
Patients in groups B, C, and D discontinued RBV
(11%, 8%, and 10%) more frequently than did the pa-
tients in group A (6%) (Fig. 2, P  .02). Frequencies of
dose reductions were higher in groups B and D (50% and
47%), the groups with lower platelet counts, compared
with groups A and C (32% and 36%, Fig. 2, P  .0001).
The magnitude of the decline in SVR from group A to D
was similar between patients who took full doses of PEG-









Plt.< 125K P1 P2
Number of patients 559 96 198 193
WBC  1,000/mm3 6.23 4.60 6.42 4.96 .0001 .0001
Neutrophils  1,000/mm3 3.41 2.48 3.44 2.64 .0001 .0001
Hemoglobin, g/dL 15.2 14.8 15.1 14.85 .002 .02
Platelets  1,000/mm3 204 101 179 93 .0001 .0001
Total bilirubin, mg/dL 0.69 0.97 0.78 1.03 .0001 .0001
Albumin, g/dL 4.01 3.79 3.89 3.64 .0001 .0001
Prothrombin time,INR 1.00 1.07 1.05 1.11 .0001 .0001
AST/ALT 0.77 0.90 0.87 0.99 .0001 .0001
ALT ratio to ULN 2.16 2.77 2.34 2.52 .003 .01
History of diabetes or fasting
Glucose  126 mg/dL 19% 27% 28% 28% .02 .004
HOMA3 13.2 19.2 18.4 17.1 .01 .11
Log HCV RNA (IU/mL) 6.49 6.44 6.41 6.27 .0001 .0001
Genotype 1 no/yes 90% 81% 93% 90% .02 .78
Liver histology
Ishak inflammation score 7.10 7.51 7.87 7.92 .0001 .0001
Fibrosis-Ishak score 3.12 3.41 5.38 5.56 .0001 .0001
Hepatocellular iron grade 0.49 0.49 0.53 0.51 .91 .52
Steatosis (0-4)4 1.26 1.40 1.46 1.28 .04 .16
Ultrasonography
Frequency of splenomegaly 18% 52% 24% 66% .0001 .0001
Endoscopy5
Frequency of gastropathy 26% 39% 44% 57% .0001 .0001
Frequency of esophogeal varices 11% 33% 28% 54% .0001 .0001
NOTE. The values listed in this table are means or percentages.
1P-values for differences in variables among the four groups were determined by t tests for means and chi-square tests for percentages.
2P-values for trends in variables from groups A through D were determined by regression analysis.
3HOMA is homeostasis model assessment; fasting insulin (U/mlL  fasting glucose (mmol/L)/22.5.
4Steatosis scores were: 0: none, 1: 5%, 2: 6%–34%, 3: 35%–64%, and 4: 64%. 5Endoscopy was only performed in the patients who entered the randomized phase
of HALT-C.
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IFN/RBV and those who had dose reductions (Fig. 3). De-
cline in SVR due to dose reduction was only significant in
this linear trend analysis in patients with cirrhosis, groups C
and D (P  .044), but was modest compared with the de-
cline in SVR based on disease severity (P  .0001).
Relative Influence of Disease Severity, Dose
Reduction, and Platelet Count on SVR
The relative effect of dose reduction or increase in dis-
ease severity on attenuation of SVR is shown in Fig. 4A.
The impact of dose reduction is marginally significant
(P  .046), whereas both groups C and D had lower SVR
than group A (P  .0005 and .0006). Because both the
increase in Ishak fibrosis score and the decrement in plate-
let count correlated with disease severity, we examined the
relative contributions of dose reduction, cirrhosis, and
platelet count  125,000/mm3 on impairment of SVR
(Fig. 4B). Cirrhosis was the most influential factor con-
tributing to reduction in SVR (P  .0001).
Management Issues
Liver Biopsy. The mean  SD of length of liver bi-
opsies was 1.83  0.89 cm, and 24% of biopsies were
fragmented. Sixty-four percent of biopsies were greater
than 1.5 cm in length, and 91% were greater than 1.0 cm
in length. The means (SDs) and ranges for length of
Fig. 1. Bars represent means and trend lines derived from logistic
regression. (A) Mean virologic response at week 20 of therapy is highest
in patients with fibrosis and platelet counts 125,000/mm3 (group A).
Patients with cirrhosis with platelet counts 125,000/mm3 were least
likely to respond (group D). (B) Sustained virologic response is lowest in
patients with cirrhosis (groups C and D).
Fig. 2. Treatment was discontinued more frequently in groups B, C,
and D. Dose reductions were more frequent in patients with platelet
counts 125,000/mm3 (groups B and D compared with A and C, P 
.0001).
Fig. 3. Bars represent means. SVR was lower in patients who dose
reduced (P /  .055), especially in patients with cirrhosis (groups
C and D) (P /  .044). Dose reduction had less effect in patients
with fibrosis without cirrhosis (groups A and B, P /  .19). Patients
who discontinued ribavirin are not included in this analysis.
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liver biopsies and percentages of patients with biopsies of
length less that 1.0 or 1.5 cm were not significantly dif-
ferent among groups A through D. Biopsy-related com-
plications occurred in 2.8% and included pain (n  20),
bruising (n  1), dehydration (n  1), hematoma (n 
1), and hypotension (n  1). Hospitalization for obser-
vation was required in 1.1%. Biopsy-related complica-
tions, including hospitalization, were similar among
groups A through D.
Side Effects of Treatment. Side effects were encoun-
tered commonly during therapy (Table 3). Flu-like symp-
toms (fatigue, arthralgia, anorexia, fever, and headache)
were common, and the frequencies were similar across
groups. Anxiety, mood swings, depression, insomnia, and
mental confusion were also commonly encountered, with
similar frequencies across groups. Alopecia was more fre-
quent in groups A and C (P  .034); anemia was more
frequent in groups B, C, and D (P  .007); and neutro-
penia (P  .0002) and thrombocytopenia (P  .0001)
were more frequent in groups B and D.
Discussion
HALT-C Trial patients are characterized by histologi-
cal evidence of advanced fibrosis or cirrhosis and by non-
response to prior interferon-based therapy. In the first
604 HALT-C Trial patients,20 we reported rates of SVR
of 11% in the subset of patients with biopsy-proven cir-
rhosis (n  233), and 23% in those without cirrhosis
(n  371) (P  .0005). Herein we report the results for all
patients enrolled in the lead-in phase of the HALT-C
Trial, and examine, in detail, the contribution of disease
severity to the impairment of virologic response. The
1,046 patients were assigned to one of four groups, A
through D, with increasing disease severity as defined, a
priori, by histological stage of fibrosis and platelet count.
Clinical, laboratory, endoscopic, and ultrasonographic
features were compared among the four groups.
The key finding of our study was profound impair-
ment of virologic response with progressively more severe
liver disease. Rates of SVR plummeted from 23% in the
group with the least severe disease (group A) to 9% in the
group with most severe disease (group D). This 61% rel-
ative reduction in SVR was much higher than the approx-
imately 10% to 30% relative reductions attributable to
advanced fibrosis or cirrhosis reported in trials of treat-
ment-naive patients.11-14,21 The principal reasons for this
difference are that all of our patients had either advanced
fibrosis (62%) or cirrhosis (38%), and all of them were
nonresponders to prior interferon-based therapy. In the
trials of treatment-naive patients, only 10% to 25% had
advanced fibrosis or cirrhosis. In addition, the entry cri-
teria for the HALT-C Trial allowed inclusion of patients
with more severe disease (platelet count 50,000/mm3),
patients that would have been excluded from entry into
the treatment-naive trials. All of these factors magnified
the impairment in virologic response and the effect of
disease severity.
In our study, SVR progressively declined from group A
to group D regardless of HCV genotype. The rate of SVR
in patients infected with HCV genotype 1 in group A was
18%, compared with 8% in patients in group D. The rate
of SVR in persons with non-1 HCV genotypes in group A
was 64%, compared with 25% in patients in group D.
Data from trials of PEG-IFN/RBV therapy in treatment-
naive patients have yielded comparable results. In the
study of Hadziyannis and co-workers, the SVR rate
among patients infected with HCV genotype 1 who had
advanced fibrosis or cirrhosis was 41%, compared with an
SVR rate of 57% in those without significant fibrosis.14
Fig. 4. (A) Disease severity had a more significant impact on SVR than
dose reduction. (B) Cirrhosis is the variable with the most significant
impact on SVR. Patients who discontinued ribavirin are not included in
this analysis.
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The rate of SVR in patients infected with HCV genotypes
2 and 3 who had advanced fibrosis or cirrhosis was 73%,
compared with an SVR of 84% in those without signifi-
cant fibrosis.14
In the current study, the percentages of patients in-
fected with HCV genotype 1 was similar and mean serum
levels of HCV RNA level lower from group A to group D.
Thus, in regression analysis, neither HCV genotype nor
blood level of HCV RNA accounted for the reduction in
SVR that occurred with increasing disease severity from
groups A to D.
Alternative explanations for diminished SVR in pa-
tients with the more advanced liver disease include an
increase in the prevalence of other established predictors
of poor response, or a high frequency of dose reductions.
We did analyze the impact of age, sex, the proportion with
African American heritage, hepatic iron, body mass index,
hepatic steatosis, and the type of prior therapy (IFN or
PEG-IFN  RBV) and found that none accounted for
the reduction in SVR from group A to group D.
Another well-established predictor of SVR is adher-
ence to prescribed doses of antiviral therapy.22 Patients
with more advanced liver disease would be more likely to
discontinue or reduce doses of medication due to cytope-
nias and increased side effects during treatment. Indeed,
we found that patients with more advanced disease
(groups B, C, and D compared with group A) were more
likely to discontinue treatment, and patients with lower
platelet counts (groups B and D compared with groups A
and C) were more likely to experience dose reductions.
Not surprisingly, we also found that dose reductions di-
minished virologic responses, primarily in patients with
cirrhosis. However, compared with disease severity, the
effect of dose reduction on impairment of virologic re-
sponse was modest (Fig. 4B).
Three treatment trials suggest further that attenuation
of doses of treatment impairs virologic response, particu-
larly in patients with the most advanced liver disease. In a
study by one of us (G.T.E.), 124 patients with decompen-
sated liver disease were treated with low, accelerating
doses of interferon alfa-2b and RBV.23 Although overall
SVR was 24%, patients infected with HCV genotype 1,
who tolerated neither full doses nor full duration of treat-
ment, had an SVR rate of 0%. Forns et al. treated 30
patients with hepatitis C and cirrhosis before liver trans-
plantation.24 Side effects were frequent; 63% required
dose reductions, and only 20% remained free of HCV
infection after transplantation. Crippin and colleagues25
treated 15 patients who had severely decompensated cir-
rhosis awaiting liver transplantation (mean  SD Child-
Turcotte-Pugh score 11.9  1.2) with low doses of
interferon or interferon/RBV, and none achieved SVR.25
Thus, patients with cirrhosis, especially those with the
most advanced liver disease, represent a population that is
“difficult-to-treat” and “difficult-to-cure.” The American
Association for the Study of Liver Disease has suggested










Number of patients 559 96 198 193
Abdominal pain 26% 20% 21% 24% .36
Alopecia 11% 7% 13% 5% .04
Anemia 22% 31% 29% 34% .004
Anorexia 19% 17% 23% 21% .54
Anxiety, mood swings 40% 41% 35% 35% .45
Arthralgias 62% 65% 64% 60% .80
Confusion, memory loss 16% 13% 15% 19% .57
Depression 20% 16% 22% 26% .15
Diaphoresis 9% 15% 8% 7% .19
Dizziness 16% 13% 18% 8% .02
Dry skin 8% 20% 11% 6% .001
Fatigue 71% 72% 72% 70% .97
Fever, URI, Flu 26% 26% 29% 27% .90
Headache 49% 41% 47% 44% .32
Infection (not URI, flu) 14% 19% 14% 16% .63
Injection site bruising, redness 22% 13% 18% 16% .08
Insomnia 35% 32% 37% 37% .77
Nausea or vomiting 42% 44% 43% 41% .95
Paresthesia 7% 5% 8% 6% .71
Rash or pruritus 51% 47% 56% 55% .36
Respiratory symptoms 35% 31% 32% 30% .52
Sinusitis 6% 5% 9% 8% .33
Neutropenia 23% 43% 29% 40% .0001
Thrombocytopenia 3% 27% 4% 44% .0001
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that only experienced clinicians, using vigilant monitor-
ing for adverse events, treat these patients.26
Maintaining the dose of antiviral therapy, particularly
in patients with cirrhosis, may be crucial to achieving
optimal virologic responses. Because dose reductions for
cytopenias were dictated by our study protocol, we could
potentially have achieved higher rates of SVR had we
maintained lower cell-count thresholds for dose reduc-
tions or relied on growth factors to counteract cytopenias.
The safety and efficacy of these approaches, however, have
been neither evaluated nor confirmed by properly con-
trolled trials.
In patients with functioning spleens, thrombocytope-
nia may be a reliable and inexpensive laboratory marker of
advanced disease and likelihood of SVR. In a previous
report from the HALT-C Trial, Lok et al.27 described a
model based on standard laboratory tests (bilirubin, as-
partate aminotransferase:alanine aminotransferase, INR,
and platelet count) that was highly predictive of the pres-
ence of cirrhosis.27 In that model, the most influential
variable was platelet count. Furthermore, in the current
study, patients without cirrhosis who had low platelet
counts (group B) had more severe liver disease than pa-
tients without cirrhosis who had normal platelet counts
(group A) but had liver disease of similar severity to that of
patients with cirrhosis and normal platelet counts (group
C). We also found that the rate of SVR in our patients
with platelet count 120,000/mm3 was only 11%, sim-
ilar to the SVR rate of patients with histologic cirrhosis.
The probability that thrombocytopenia is a faithful
marker of advanced disease in patients classified histolog-
ically as having fibrosis but lacking cirrhosis is supported
by our findings that, among the individuals in group B,
33% had varices, 39% had portal hypertensive gastropa-
thy, and 52% had splenomegaly.
We conclude that more advanced liver disease, espe-
cially cirrhosis, independently impairs the response to in-
terferon-based antiviral therapy. Although mechanisms
were not defined by—and are well beyond the scope of—
our study, potential factors in more advanced disease that
could diminish response might include microcirculatory
alteration by extensive fibrosis, impaired uptake or metab-
olism of antiviral medications, interference with immune
mechanisms of viral clearance by cytokines or other fac-
tors mediating fibrosis, and refractoriness to the inter-
feron signaling pathway. Improvement of responses to
currently available therapy in patients with advanced fi-
brosis and cirrhosis will require a better understanding of
the mechanisms underlying the inhibitory effect of dis-
ease severity on virologic response. Our results also em-
phasize the urgent need for new and better drugs to
eradicate HCV in those most in need of effective treat-
ment, namely, the patients with advanced liver disease.
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